Head to head
Exelixis vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: EXEL · VRTX
EXEL
Exelixis
58.44+0.19%
1-year price shape — +47% over the period
Quant Rating B · 81/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| EXEL | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 58.44 | 505.64 |
| Change today | +0.19% | +0.66% |
| 1-year return | +47.5% | +23.2% |
| Market cap | $14.48B | $128.16B |
| 52-week range | 33.76 – 61.14 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | 18.38 | 29.45 |
| P/E percentile, own 5-yr range | 22nd | 74th |
| P/B | 7.85 | 6.33 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 2.78 | 15.32 |
| Net profit (TTM) | $688.83M | $3.88B |
| Revenue (TTM) | $2.44B | $12.59B |
| Revenue growth (YoY) | +10.6% | +12.5% |
| Gross margin | 96.5% | 86.0% |
| Operating margin | 40.7% | 37.9% |
| Net margin | 35.3% | 35.0% |
| Free cash flow (TTM) | $1.16B | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 106.5% | 97.2% |
| Insider activity (12mo) | 17 buy / 33 sell | 25 buy / 25 sell |
| Short interest (% of float) | 10.7% | 1.9% |
| Analyst consensus | 50% buy / 33% hold / 17% sell (6) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $54 (-8%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | B (81) | C (67) |
| Company | ||
| Employees | 4,600 | 6,400 |
| Founded | 1994 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.